4.1 Review

The role of MRI in active surveillance of prostate cancer

期刊

CURRENT OPINION IN UROLOGY
卷 23, 期 3, 页码 261-267

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOU.0b013e32835f899f

关键词

active surveillance; MRI; MRI-targeted biopsy; prostate cancer

资金

  1. GSK
  2. Janssen
  3. Lily
  4. Wellcome Trust
  5. Department of Health
  6. Prostate Cancer Charity
  7. Bob Champion Trust
  8. Sanofi Aventis
  9. STEBA Biotech
  10. AMD
  11. USHIFU
  12. National Institute for Health Research [09/22/67] Funding Source: researchfish

向作者/读者索取更多资源

Purpose of review The aim of active surveillance is to avoid radical treatment and its side-effects in men who have truly low risk prostate cancer, whilst offering radical treatment to those men who are at higher risk of local progression or metastatic disease. The traditional tools used to attribute these risk categories are prostate specific antigen, digital rectal examination, transrectal biopsy and their repeated application over time. MRI is emerging as a tool which may be able to more accurately determine the risk of significant disease at diagnosis and progression of disease over time. This review will examine the role of MRI in men on active surveillance. Recent findings The body of work on MRI as a tool for the detection of significant cancer is rapidly increasing, both in men undergoing initial assessment for prostate cancer risk, and in those who have low risk cancer on standard transrectal ultrasound guided biopsy. In addition, the use of MRI as a tool to detect change in prostate cancer is being explored by a small number of groups. Summary Multiparametric MRI is a useful tool in the initial assessment and surveillance of men who choose to avoid radical treatment when first diagnosed with localized prostate cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据